Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

NCT00776984 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

453

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: tiotropium 5mcg/day
DRUG: placebo

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]